All the news Showing 10 of 53 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care Liz Highleyman / 29 April 2013 An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors ... Daclatasvir/asunaprevir effective in difficult-to-treat HCV populations Healio Hepatology / 09 April 2013 Telaprevir shows promise in black patients with genotype 1 HCV Healio / 12 March 2013 Victrelis (boceprevir) label updates FDA / 18 February 2013 Nucleotide Polymerase Inhibitors - The Search For A Safe Interferon Free Trial HCV New Drugs Research / 10 January 2013 Gilead Provides Update on Hepatitis C Development Programs Gilead press release / 08 January 2013 Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring Liz Highleyman / 05 December 2012 Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ... Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5885 Liz Highleyman / 15 November 2012 The hepatitis C polymerase inhibitor sofosbuvir produced high rates of sustained virological response in genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data presented this week ... Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations Abbott press release / 14 November 2012 High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype Keith Alcorn / 12 November 2012 Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb to treat hepatitis C was highly effective in curing the infection in previous null responders to treatment with HCV genotype 1b infection, ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive